Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy

被引:52
|
作者
Guerra, J. L. Lopez [1 ,3 ]
Gomez, D. R. [1 ]
Lin, S. H. [1 ]
Levy, L. B. [1 ]
Zhuang, Y. [1 ]
Komaki, R. [1 ]
Jaen, J. [3 ]
Vaporciyan, A. A. [2 ]
Swisher, S. G. [2 ]
Cox, J. D. [1 ]
Liao, Z. [1 ]
Rice, D. C. [2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Surg, Houston, TX 77030 USA
[3] Grp IMO, Dept Radiat Oncol, Inst Madrileno Oncol, Madrid, Spain
基金
美国国家卫生研究院;
关键词
non-small-cell lung cancer; recurrence; thoracic surgery; CLINICAL-PRACTICE GUIDELINES; EARLY-STAGE; POSTOPERATIVE RADIOTHERAPY; SURVIVAL; RATES; CHEMOTHERAPY; PROGNOSIS; PATTERNS; SURGERY; WOMEN;
D O I
10.1093/annonc/mds274
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to evaluate the actuarial risk of local and regional failure in patients with completely resected non-small-cell lung cancer (NSCLC), and to assess surgical and pathological factors affecting this risk. Between January 1998 and December 2009, 1402 consecutive stage I-III (N0-N1) NSCLC patients underwent complete resection without adjuvant radiation therapy. The median follow-up was 42 months. Local-regional recurrence was identified in 9% of patients, with local failure alone in 3% of patients, regional failure alone in 4% of patients, and both local and regional failure simultaneously in 2% of patients. Patients who had local failure were found to be at increased risk of mortality. By multivariate analyses, three variables were shown to be independently significant risk factors for local [surgical procedure (single/multiple wedges + segmentectomy versus lobectomy + bilobectomy + pneumonectomy), tumor size > 2.7 cm, and visceral pleural invasion] and regional (pathologic N1 stage, visceral pleural invasion, and lymphovascular space invasion, LVI) recurrence, respectively. Patients with N0-N1 disease have low rates of locoregional recurrence after surgical resection. However, several prognostic factors can be identified that increase this risk and identify patients who may benefit from adjuvant treatment.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 50 条
  • [41] Molecular risk factors for locoregional recurrence in resected non-small cell lung cancer
    Guo, Wei
    Zhang, Tao
    Li, Runze
    Chen, Xiaoxi
    Pang, Jiaohui
    Bao, Hua
    Wu, Xue
    Shao, Yang
    Qiu, Bin
    Gao, Shugeng
    He, Jie
    [J]. CANCER MEDICINE, 2023, 12 (14): : 15026 - 15036
  • [42] Optimal sequencing of adjuvant chemotherapy and radiation therapy in resected non-small cell lung cancer with pathological N2 disease
    Rodrigues, George
    [J]. JOURNAL OF THORACIC DISEASE, 2016, 8 (06)
  • [43] Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer
    Yano, Tokujiro
    Okamoto, Tatsuro
    Haro, Akira
    Fukuyama, Seiichi
    Yoshida, Tsukihisa
    Kohno, Mikihiro
    Maehara, Yoshihiko
    [J]. LUNG CANCER, 2013, 82 (03) : 431 - 435
  • [44] Use of PET/CT for patient selection and radiation therapy target volume definition in patients with non-small-cell lung cancer
    MacManus, Michael P.
    [J]. LUNG CANCER MANAGEMENT, 2013, 2 (05) : 391 - 405
  • [45] Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
    Le Chevalier, T
    Arriagada, R
    Le Péchoux, C
    Grunenwald, D
    Dunant, A
    Pignon, JP
    Tarayre, M
    Abratt, R
    Arriagada, R
    Bergman, B
    Gralla, R
    Grunenwald, D
    Le Chevalier, T
    Orlowski, T
    Papadakis, E
    Pinel, MIS
    Araujo, C
    Della Torre, H
    de Solchaga, MM
    Abdi, E
    Blum, R
    Ball, D
    Basser, R
    De Boer, R
    Bishop, J
    Brigham, B
    Davis, S
    Fox, D
    Richardson, G
    Wyld, D
    Pirker, R
    Humblet, Y
    Delaunois, L
    Van Meerbeeck, JP
    Germonpre, P
    Vansteenkiste, J
    Nackaerts, K
    Pinel, MIS
    Vauthier, G
    Younes, RN
    Arriagada, R
    Baeza, R
    Carvajal, P
    Kleinman, S
    Orlandi, L
    Castro, C
    Godoy, J
    Kosatova, K
    Gaafar, R
    Azarian, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (04): : 351 - 360
  • [46] Definitive Local Therapy for Oligo-recurrence in Patients With Completely Resected Non-small Cell Lung Cancer
    Matsuguma, Haruhisa
    Nakahara, Rie
    Wakamatsu, Ikuma
    Kishikawa, Takayuki
    Sugiyama, Tomohide
    Nakamura, Yoichi
    Kasai, Takashi
    Kamiyama, Yukari
    Hoshi, Nobuo
    Inoue, Koichi
    Katano, Susumu
    Yokoi, Kohei
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (03): : 210 - 217
  • [47] ACR Appropriateness Criteria® Induction and Adjuvant Therapy for N2 Non-small-cell Lung Cancer
    Willers, Henning
    Stinchcombe, Thomas E.
    Barriger, R. Bryan
    Chetty, Indrin J.
    Ginsburg, Mark E.
    Kestin, Larry L.
    Kumar, Sanath
    Loo, Billy W., Jr.
    Movsas, Benjamin
    Rimner, Andreas
    Rosenzweig, Kenneth E.
    Videtic, Gregory M. M.
    Chang, Joe Yujiao
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (02): : 197 - 205
  • [48] Non-Small Cell Lung Cancer: Prognostic Importance of Positive FDG PET Findings in the Mediastinum for Patients with N0-N1 Disease at Pathologic Analysis
    Xie, Liyi
    Saynak, Mert
    Veeramachaneni, Nirmal K.
    Fried, David V.
    Jagtap, Mandar R.
    Chiu, Wing Keung
    Higginson, Daniel S.
    Lawrence, Michael V.
    Khandani, Amir H.
    Qaqish, Bahjat F.
    Chen, Ronald C.
    Marks, Lawrence B.
    [J]. RADIOLOGY, 2011, 261 (01) : 226 - 234
  • [49] BLOOD-VESSEL INVASION BY TUMOR-CELLS PREDICTS RECURRENCE IN COMPLETELY RESECTED T1-N0-M0 NON-SMALL-CELL LUNG-CANCER
    MACCHIARINI, P
    FONTANINI, G
    HARDIN, MJ
    CHUANCHIEH, H
    BIGINI, D
    VIGNATI, S
    PINGITORE, R
    ANGELETTI, CA
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 106 (01): : 80 - 89
  • [50] A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer
    Krivitsky, Timur A.
    Wright, Gavin M.
    Al Zaidi, Muteb
    [J]. JOURNAL OF THORACIC DISEASE, 2021, 13 (01) : 149 - 159